宣泰医药(688247) - 2025 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2025 was CNY 108,926,965.45, a decrease of 2.23% compared to CNY 111,411,602.18 in the same period last year[4]. - Net profit attributable to shareholders was CNY 20,489,309.09, down 10.51% from CNY 22,895,905.48 year-on-year[4]. - The net profit after deducting non-recurring gains and losses was CNY 19,067,636.31, reflecting a decrease of 12.33% compared to CNY 21,748,197.24 in the previous year[4]. - Total operating revenue for Q1 2025 was ¥108,926,965.45, a decrease of 2.2% compared to ¥111,411,602.18 in Q1 2024[18]. - Net profit for Q1 2025 was ¥20,489,309.09, down 10.5% from ¥22,895,905.48 in Q1 2024[19]. - Operating profit for Q1 2025 was ¥23,351,343.17, a decrease of 12.5% from ¥26,588,025.98 in Q1 2024[18]. - Total operating costs for Q1 2025 were ¥88,936,260.56, an increase of 3.5% from ¥85,556,447.58 in Q1 2024[18]. - Basic and diluted earnings per share for Q1 2025 remained at ¥0.05, unchanged from Q1 2024[19]. - Other comprehensive income after tax for Q1 2025 was -¥107.34, reflecting a decrease compared to the previous year[19]. Cash Flow and Investments - Operating cash flow for the period increased significantly by 127.92%, reaching CNY 65,588,203.74, compared to CNY 28,776,793.07 in the same period last year[4]. - Cash flow from operating activities for Q1 2025 was ¥65,588,203.74, significantly up from ¥28,776,793.07 in Q1 2024[23]. - Cash flow from investing activities for Q1 2025 was -¥142,392,271.43, an improvement from -¥409,037,270.16 in Q1 2024[24]. - Cash and cash equivalents decreased to RMB 148,955,862.02 from RMB 225,785,781.43, representing a decline of approximately 34.1%[13]. - Cash and cash equivalents at the end of Q1 2025 were ¥148,955,862.02, down from ¥229,422,987.49 at the end of Q1 2024[24]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 1,468,663,744.92, an increase of 1.06% from CNY 1,453,304,093.20 at the end of the previous year[5]. - As of March 31, 2025, the total assets of Shanghai Xuantai Pharmaceutical Technology Co., Ltd. amounted to RMB 1,468,663,744.92, an increase from RMB 1,453,304,093.20 as of December 31, 2024, reflecting a growth of approximately 1.4%[13]. - The company's current assets totaled RMB 983,289,086.99, slightly up from RMB 976,317,889.19, indicating a growth of about 0.99%[13]. - The accounts receivable decreased significantly from RMB 103,524,626.45 to RMB 63,321,304.26, a reduction of about 38.9%[13]. - The total liabilities decreased from RMB 180,299,755.44 to RMB 175,170,098.07, a decline of approximately 2.4%[15]. - The company's equity attributable to shareholders increased from RMB 1,273,004,337.76 to RMB 1,293,493,646.85, reflecting a growth of about 1.6%[15]. - The inventory remained relatively stable, with a slight decrease from RMB 102,418,450.82 to RMB 102,397,398.38[14]. - The non-current assets totaled RMB 485,374,657.93, up from RMB 476,986,204.01, indicating an increase of approximately 1.6%[14]. Research and Development - R&D investment totaled CNY 12,449,732.66, a decrease of 19.44% from CNY 15,454,452.53 year-on-year, representing 11.43% of revenue, down from 13.87%[5]. - Research and development expenses for Q1 2025 were ¥12,449,732.66, a decrease of 19.5% compared to ¥15,454,452.53 in Q1 2024[18]. Shareholder Information - The company had a total of 8,389 preferred shareholders with restored voting rights at the end of the reporting period[8]. - The largest shareholder, Shanghai Lianhe Investment Co., Ltd., holds 51.40% of the shares, totaling 233,000,000 shares[10]. - The company has not reported any significant changes in major shareholders or their participation in financing activities during the reporting period[12]. Non-Recurring Gains and Losses - Non-recurring gains and losses for the period amounted to CNY 1,421,672.78, with government subsidies contributing CNY 506,833.79[6][7]. - The weighted average return on equity decreased to 1.60%, down 0.28 percentage points from 1.88% in the previous year[5].